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Objectives. We sought to utilize terminal stored intracardiac
electrograms (EGMs) to study the electrophysiologic events that
accompany mortality in patients with third-generation implant-
able cardioverter-defibrillators (ICDs).
Background. Despite their ability to effectively terminate ven-
tricular tachyarrhythmias, cardiac mortality in patients with
ICDs remains high. The mechanisms and modes of death in these
patients are not well understood.
Methods. We retrospectively analyzed clinical data and stored
EGMs from patients enrolled in the clinical trial of the Ventritex
Cadence ICD. Of the 1,729 patients 119 died during 6 years of
follow-up. The final recorded EGM was reviewed. Postimplant
EGMs as well as 50 control EGMs were used to define normal
EGM characteristics.
Results. There were 36 noncardiac deaths (30%) and 83 cardiac
deaths (70%). Of the cardiac deaths, 55 (66%) were nonsudden
and 28 (34%) were sudden. When cardiac deaths were analyzed, 46
(55%) had no stored EGMs within 1 h of death, implying that the
deaths were not directly related to tachyarrhythmias. In 37
cardiac deaths (18 nonsudden, 19 sudden), stored EGMs were
present within 1 h of death. In these 37 deaths, the final EGM
recorded was wide (>158 ms) in 33 (89%). Wide EGMs were
interpreted as ventricular tachycardia in 27 and ventricular
fibrillation in 6. In 13 of the 33 patients (39%) with wide EGMs,
therapy was not delivered by the ICD, as it incorrectly detected a
spontaneous termination of the arrhythmia. EGMs were signifi-
cantly wider if recorded within 1 h, as compared with those
recorded from 1 to 48 h before death (261 6 124 vs. 181 6 93 ms,
p 5 0.04).
Conclusions. Only 37 patients (31%) who died after placement
of an ICD had a stored EGM within 1 h of the time of death,
suggesting that the majority of deaths (69%) were not the imme-
diate result of a tachyarrhythmia. When EGMs were recorded,
they were wide in 89% of patients. These wide EGMs most likely
represent intracardiac recordings of electromechanical dissocia-
tion. Thus, of the 119 deaths, 112 (94%) were not the immediate
result of a tachyarrhythmia.
(J Am Coll Cardiol 1998;32:1056–62)
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Sudden cardiac death (SCD) is responsible for ;300,000
deaths annually in the United States (1). The understanding of
the causes of sudden death has evolved dramatically over the
past 20 years. Mobile cardiac rhythm recordings have revealed
a high incidence of ventricular tachycardia (VT) and ventric-
ular fibrillation (VF) in patients who have a sudden cardiac
death (2–4). This leads to the concept that the prevention or
rapid treatment of VT and VF could prevent SCD. In response
to this concept, the implantable cardioverter-defibrillator
(ICD) was developed. Currently available ICDs can efficiently
recognize and terminate ventricular tachyarrhythmias in the
vast majority of cases (5,6). These third-generation ICDs are
also able to store intracardiac electrograms (EGMs) from
tachyarrhythmic episodes. These EGMs can be retrospectively
analyzed to aid in the diagnosis of arrhythmia (7). Several
retrospective and prospective studies have suggested that the
use of ICDs decreases the rate of SCD in high risk patients
(8–12). Despite the ability of ICDs to detect and terminate
ventricular tachyarrhythmias, overall mortality for patients
with depressed ventricular function who have undergone
placement of ICDs remains substantial (8,13).
Several investigators have investigated the clinical modes of
death in patients with earlier generation ICDs. These studies
were limited by the lack of EGM data from the ICD during the
terminal events. This study was undertaken to analyze the
stored EGMs from patients who had a third-generation ICD
and subsequently died. These EGMs were compared with
clinical data and previously stored EGMs in an attempt to
identify the modes of death, as well as the EGM characteristics
associated with these deaths.
Methods
Initial clinical trial. The Ventritex Cadence is a third-
generation noncommitted ICD capable of storing EGMs sur-
rounding both delivered and aborted antitachycardia therapy
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(14). A 33-s EGM is recorded by the device, sampled at
256 Hz, from an endocardial or epicardial sensing electrode
(Fig. 1). The gain setting is automatically adjusted in response
to amplitude changes in the sensed signals. In addition, the
gain setting is automatically increased by one step (1.5 times
the previous gain) after the delivery of a shock. If the ensuing
signal saturates the device filter, the recording gain immedi-
ately returns to the preshock setting. If three subsequent
sensed signals continue to saturate the filter, the recording gain
decreases further. The stored EGMs can subsequently be
retrieved from the ICD through a programmer, during routine
interrogation, and printed at a paper speed of 25 mm/s (14).
The ICD interpretation of the arrhythmia is provided during
interrogation. In addition, the date and time of each event are
recorded.
The clinical trial of this device enrolled patients from July
1989 until April 1993. Clinical follow-up was obtained until
April 1995. Over the course of the trial, 1,729 patients had an
ICD placed. The following clinical data were collected for each
patient at the time of device implantation: the patient’s age,
gender, ejection fraction (calculated by echocardiography,
radionuclide scans or left ventriculography), weight, height,
presence or absence of pacemaker, etiology of structural heart
disease, documented arrhythmias (arrhythmia morphology and
cycle length), antiarrhythmic medications at the time of im-
plantation, antiarrhythmic medications that failed before de-
vice implantation and ICD lead configuration and placement
(unpublished data, 1989). In addition, each patient underwent
device testing during implantation. At the time of implanta-
tion, all patients underwent induction of VF, with rescue
shocking by the ICD, to ensure proper ICD function. The
stored EGMs from these postimplantation test episodes were
used as paired controls, to define the normal EGM width after
therapy delivery in each patient.
When a patient in the study died, the device was interro-
gated and all stored EGMs were retrieved. The EGMs were
collected and returned to the study sponsor and the Food and
Drug Administration for further review. After receiving writ-
ten permission from the trial investigators, we reviewed the
clinical data and stored EGMs for all patients who died before
April 1995. The available clinical data, including physician
notes at the time of death (available in 98% of cases), autopsy
data (available in 15% of cases) and death certificates (avail-
able in 2% of cases) were reviewed in an attempt to determine
the exact cause of death.
Abbreviations and Acronyms
CAST 5 Cardiac Arrhythmia Suppression Trial
EGM 5 intracardiac electrogram
EMD 5 electromechanical dissociation
ICD 5 implantable cardioverter-defibrillator
NSCD 5 nonsudden cardiac death
SCD 5 sudden cardiac death
VF 5 ventricular fibrillation
VT 5 ventricular tachycardia
Figure 1. Stored EGM from the Ca-
dence ICD in a control subject. The
EGM is recorded at 256 Hz from a
bipolar sensing lead in the right ventri-
cle. The time, in seconds, is displayed at
the bottom of the strip. The sharp sig-
nals, lasting ;100 ms, represent ven-
tricular depolarization. This EGM ini-
tially depicts a rhythm, consistent with
atrial fibrillation (A). The rhythm spon-
taneously converts into a more rapid
rhythm (B), which meets detection cri-
teria for VT, and antitachycardia pac-
ing is delivered (C) in an attempt to
terminate the rhythm. This intervention
causes an acceleration of the arrhyth-
mia (D), and a shock is delivered (E),
with the resultant termination of the
tachyarrhythmia (F) and resumption of
a slower rhythm, consistent with sinus
rhythm.
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In addition, the clinical characteristics and stored EGMs
from 50 study patients who were alive as of April 1995 were
used as a control group. These EGMs were recorded during
either postimplantation testing or spontaneous episodes of
ventricular tachyarrhythmias. All EGMs were recorded after
delivery of an appropriate shock by the ICD.
Classification of clinical cause of death. The cause and
time of death were determined by reviewing the available
clinical data, including physician notes at the time of death,
death certificates and autopsy data. In cases where the precise
time of death was not available, the death was assumed to have
occurred .1 h from the final recorded EGM.
Deaths were classified using a modified Cardiac Arrhythmia
Suppression Trial (CAST) approach, as described by Pratt et
al. (15). Deaths were classified as sudden cardiac (SCD) if they
were unexpected and occurred within 1 h of the onset of new
symptoms or if the death was unwitnessed and unexpected,
unless a specific noncardiac cause could be confirmed. Deaths
were classified as nonsudden cardiac (NSCD) if they were of
cardiac origin but did not meet the criteria for SCD. Deaths
were classified as noncardiac if they occurred as a result of
factors that were not primarily cardiac. Deaths that were due
to noncardiac causes were also reviewed.
Analysis of terminal EGMs. Two EGMs were reviewed for
each patient who had a cardiac death—the EGM obtained at
postimplantation device testing and the final stored EGM
before death. The date and time of each EGM were recorded.
EGMs recorded within 1 h of the clinically derived time of
death were considered relevant to the death. The stored EGMs
were further reviewed to determine the type of arrhythmia
detected, the accuracy of the device in diagnosing the arrhyth-
mia, the therapy delivered by the device, the rhythm present
after therapy delivery and the accuracy of the device in
recognizing the final rhythm. In addition, the width of the
EGM signal was measured manually by two independent
observers. EGM signals .2 SD above the EGM signal width
obtained at postimplantation testing were classified as wide.
The width of the postshock EGM signal from the patients who
survived the trial was also measured.
Statistical analysis. Statistical analysis was performed us-
ing StatSoft Statistica Software, Version 4.1. Continuous vari-
ables were expressed as the mean value 6 SD. Continuous
variables were compared using the Student t test and analysis
of variance. For multiple comparisons, the Tukey Honest
Significance Difference (HSD) for Unequal Sample Sizes–
Spjotvoll & Stoline test were used in conjunction with analysis
of variance. Dichotomous variables were compared using the
chi-square test. p values ,0.05 were considered significant.
Results
Baseline characteristics. The baseline characteristics of
the study group and control group are shown in Table 1. The
two groups were similar in terms of age, ejection fraction,
etiology of cardiac disease and indications for device implan-
tation. The majority of study patients (89%) had coronary
artery disease, severely decreased left ventricular systolic func-
tion (mean left ventricular ejection fraction 28 6 11%) and
monomorphic VT as the indication for implantation of the
device (85%) and died within a relatively short time after
device implantation (11.5 6 11.9 months). Fifty-nine percent
of the patients were receiving antiarrhythmic medications at
the time of device implantation. The sensing electrode was
endocardial in 40 patients (33%) and epicardial in 79 (66%).
Clinical causes of death. The clinical causes of death in the
study group are depicted in Figure 2. Eighty-three deaths were
due to cardiac causes, 28 of which were sudden and 55 were
nonsudden. There were 36 noncardiac deaths (Table 2). In
three noncardiac deaths, the cause of death could not accu-
rately be determined.
Time of death. The clinically derived time of death in the
study group could be accurately identified in 70 (84%) of the
83 cardiac deaths. The precise time (within 1 h) of the re-
maining 13 deaths could not be accurately determined. These
Table 1. Baseline Clinical Characteristics of Patients Who Died
During the Initial Trial of Ventritex Cadence Implantable
Cardioverter-Defibrillator and of Control Subjects Who Survived the
Trial
Patients
(n 5 119)
Control Subjects
(n 5 50)
p
Value
Age (years) 67.1 6 8.2 64.8 6 9.7 0.11
Gender (%male) 90 82 0.71
Ejection fraction (%) 28 6 12 30 6 12 0.52
Time to death (months) 11.5 6 11.9 N/A
Underlying cardiac disease (%)
Coronary artery disease 89 76 NS
Dilated cardiomyopathy 11 24 NS
Indication for implantation* (%)
MVT 85 82 NS
PVT/VF 15 18 NS
*Fifteen percent of patients had multiple indications for device implantation.
These patients were classified as having MVT as their indication for implanta-
tion. Data are presented as the mean value 6 SD or percentage of patients.
MVT 5 monomorphic ventricular tachycardia; PVT 5 polymorphic ventricular
tachycardia; VF 5 ventricular fibrillation.
Figure 2. Clinical causes of mortality. Cardiac deaths are divided into
sudden cardiac deaths and nonsudden cardiac deaths based on the
modified CAST system. EGM signifies the presence of stored electro-
grams within 1 h of the clinically determined time of death. Wide
denotes wide signals on the terminal EGM, .158 ms. Narrow denotes
terminal EGM signals .158 ms.
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deaths were regarded as occurring .1 h from the time of the
final EGM.
EGMs and clinical cause of death. Cardiac mortality. The
final stored EGMs were reviewed for all patients who had a
cardiac death. Of the 83 patients who had a cardiac death (28
sudden and 55 nonsudden), stored EGMs had been recorded
within the final hour of life in 37 (19 sudden and 18 nonsud-
den), indicating that the device had sensed a heart rate that
exceeded the tachycardia detection rate. Thus, there were no
stored EGMs in the final hour of life in 46 of patients (55%),
indicating that the device did not detect a heart rate exceeding
the tachycardia detection rate. Given the proven ability of the
device to accurately detect ventricular tachyarrhythmias (6),
the remaining 46 deaths most likely occurred in the absence of
a sustained ventricular tachyarrhythmia. These deaths were
most likely associated with a bradyarrhythmia or electrome-
chanical dissociation (EMD) that was not recorded.
In 18 (33%) of the 55 NSCDs, stored EGMs were recorded
within 1 h of the time of death, indicating that the heart rate
had exceeded the tachycardia detection rate. The ICD de-
tected the resumption of what it perceived as sinus rhythm at
the conclusion of each of these episodes. In 12 of these deaths
(22%), the stored EGM was recorded within 10 min of the
time of death, suggesting that the device was successful in
terminating the perceived arrhythmia, but was unable to
terminate the condition resulting in the death of the patient. In
the remaining 43 patients (78%), EGMs were not recorded in
the final minutes before death.
In 19 (68%) of the 28 SCDs, EGMs were stored from within
1 h of the clinically determined time of death, indicating that
the heart rate had exceeded the tachycardia detection rate.
The ICD detected the resumption of what it perceived as sinus
rhythm at the conclusion of each of these episodes. In 15 of
these deaths (54%), the stored EGM was recorded within
10 min of the time of death, suggesting that the device was
successful in terminating the perceived arrhythmia, but was
unable to terminate the condition resulting in the death of the
patient. In the remaining 13 patients (46%), EGMs were not
recorded in the final minutes before death.
Noncardiac mortality. The final stored EGM was reviewed
for all patients who had a noncardiac death. Of the 36 patients
who had a noncardiac death, stored EGMs had been recorded
within the final hour of life in one. This patient was admitted
with intractable bleeding from a peptic ulcer. He had one
stored EGM, which revealed a tachyarrhythmia. The arrhyth-
mia was appropriately detected and treated by the device, with
the resumption of a nontachyarrhythmic rhythm, consistent
with sinus rhythm.
Characteristics of terminal EGMs. EGM width. The rela-
tion between EGM width and time to death for cardiac deaths
with stored EGMs is presented in Figure 3. The mean EGM
width in these patients at postimplantation device testing was
113 6 19 ms. In the control group, the mean EGM width after
delivery of therapy was 108 6 20 ms. There was no significant
difference in EGM width between the control group and the
study group at postimplantation testing (p 5 0.91). EGMs that
preceded death by ,1 h were significantly wider than those
that preceded death by .1 h (261 6 124 vs. 181 6 93 ms, p 5
0.01). The EGMS from those patients who died ,1 h after the
final stored event were significantly wider than those obtained
during postimplantation testing (181 6 93 vs. 113 6 19 ms, p 5
0.05).
The relation between EGM width and clinical cause of
death was studied. Patients who had a SCD within 1 h of the
final ICD-detected episode had an EGM width 295 6 150 ms.
The signal width of the final recorded signal in patients who
had a NSCD within 1 h of the final EGM was 227 6 69 ms (p 5
0.08) (Fig. 4). Wide EGM signals were present in 17 (89%) of
the 19 patients who had a SCD and 13 (72%) of the 18 patients
who had a NSCD (p 5 NS).
Wide EGMs. There were 30 wide EGMs recorded in the
final hour of life among the patients who had a cardiac death.
Table 2. Noncardiac Mortality
Cause No. of Deaths
Infection 8
Renal failure 5
Pulmonary embolus 5
Cancer 6
Stroke 3
Other* 6
Unknown† 3
Total 36
*Other noncardiac causes includes peripheral vascular disease and intestinal
ischemia. †Unknown cause of death, with no evidence of a cardiac cause.
Figure 3. Relation between EGM width and time between recording
and death. EGM width represents the width of the final EGM signal
recorded. .1 Hour denotes those deaths that occurred .1 h after the
final EGM was recorded. ,1 Hour denotes those deaths that occurred
within 1 h of the final EGM recording. PIT denotes the EGM width
recorded at postimplantation device testing for each patient that
subsequently died. The control group represents the postshock EGM
width obtained during device testing in patients who did not die during
the trial. Device testing occurred immediately after device implanta-
tion in all cases. *p 5 0.01; **p 5 0.05; ***p 5 0.91; ****p 5 0.03;
*****p 5 .000007; ******p 5 0.000007.
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These EGMs were interpreted by the ICD as VT in 26 (86%)
and VF in 6 (14%). The device delivered therapy in 18 (55%)
of the 33 wide EGMs. In 13 patients (43%), the ICD ultimately
delivered a shock to treat the rhythm. In 5 patients (17%), the
ICD only delivered antitachycardia pacing. In 12 patients
(40%), the ICD delivered no therapy because the ICD falsely
detected spontaneous termination of the perceived arrhyth-
mia. Examples of wide EGMs are presented in Figure 5.
The cycle length of the wide EGM recorded in the final
hour of life was 848 6 247 ms in patients who had a SCD and
757 6 251 in patients who had a NSCD. There was no
significant difference in cycle length between the two groups
(p 5 0.3) (Table 3).
Discussion
Current attempts to treat SCD are based on the premise
that the vast majority of these episodes are due to ventricular
tachyarrhythmias. However, recent evidence suggests that in-
tractable bradyarrhythmias and EMD may cause some SCDs.
We undertook this study to further define the arrhythmias that
immediately precede cardiac death in patients with ICDs.
Given the proven ability of ICDs to detect tachyarrhythmias
(10,11), as well as the low incidence of device failure, deaths
that were not accompanied by ICD discharges (thus stored
EGMs) within the final hour of life are unlikely to be related
to tachyarrhythmias. There were no discharges in 55% of the
cardiac deaths within 1 day of death, and among those with
discharges in the final day of life, there were no discharges in
the final 10 min of life in 37%, implying that a sizable number
of patients with cardiac death did not die as the direct result of
a tachyarrhythmia. If cardiac deaths are further examined,
67% of NSCDs and 32% of SCDs did not occur with an ICD
discharge in the final day of life. Even among patients with an
ICD discharge in the final day of life, few (21% of NSCDs and
33% of SCDs) had an ICD discharge within the final 10 min of
life. This implies that the majority of patients in both groups
did not die as the direct result of a tachyarrhythmia. These
deaths were most likely the result of EMD and/or brady-
arrhythmia, which were fatal despite the back-up pacing capa-
bilities of the ICD. There is no evidence that these deaths were
due to the inability of the device to effectively terminate
tachyarrhythmias.
When cardiac death was accompanied by ICD discharge in
the final hour of life, the EGM signals that accompanied the
final episodes were usually wide and fractionated, which were
misinterpreted by the device as representing ventricular tachy-
arrhythmias. In 39% of these cases, the device detected a
spontaneous termination of the tachyarrhythmia, despite the
fact that the signals were unchanged. The remainder of the
patients with wide EGMs received therapy from the device,
which was unsuccessful. The inability of the ICD to convert
these wide signals to normal sinus rhythm, as well as the
increased prevalence of wide EGMs as the clinically deter-
mined time of death approaches, suggests that these wide
signals most likely represent EMD, which current ICD algo-
rithms are unlikely to recognize or terminate. It is unlikely that
these wide EGMs represent episodes of refractory VT or VF,
as they occurred at rates below 100/min. It is also unlikely that
these fractionated EGMs were due to the development of
intraventricular conduction abnormalities that developed in
the interval between device implantation and death. Although
morphologic changes in EGM characteristics have been asso-
ciated with the development of bundle branch block (16), no
changes in EGM width have been reported. The possibility
that these EGM signals represent potentials recorded within
the zone of slow conduction of a reentrant arrhythmia is
remote, as they had not been seen during earlier tachyarrhyth-
mic events in the same patients or in the control group. The
wide EGMs noted represent only a proportion of all episodes
of EMD, as many episodes may have been associated with
EGM signals that were not excessively wide or fractionated.
The majority of cardiac deaths in this study group appear to
be due to EMD or intractable bradyarrhythmias, or both. This
is consistent with the recognized efficacy of ICDs in terminat-
ing ventricular tachyarrhythmias. Our data agree with those of
Luu et al. (17), who reported that bradyarrhythmias and EMD
were responsible for a large fraction of sudden death in
patients awaiting heart transplantation. Changes in the under-
lying cardiac substrate, such as progression of underlying
disease caused by ischemia or electrolyte imbalances, may limit
the ability of the ICD to prevent all episodes of SCD.
There are several limitations associated with our retrospec-
tive study. Attempts to precisely ascertain the cause of death
were hampered by a relative lack of autopsy data. Previous
reports have documented the importance of autopsy data to
precisely determine the cause of death (16).
There are limitations in the digital recordings produced by
this device. The quality of a digital signal is dependent on the
sampling rate as well as the gain used for the recording. We
were unable to ascertain the precise gain settings used during
each event. However, it is unlikely that the wide EGMs we
observed were the result of changes in the recording gain of the
ICD. The protocol by which the Cadence automatically
changes gain after the delivery of a shock could cause an initial
Figure 4. EGM width and cardiac death. Relation between EGM
width and cardiac cause of death. EGM width represents the width of
the final EGM signal recorded. *p 5 0.08.
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“overgaining” of signals, but this would quickly be corrected.
The wide EGM signals we report persisted without appreciable
change for a substantial period. In addition, wide EGMs were
observed exclusively in close proximity to the time of death. If
these signals were the result of device malfunction, lead
fracture or electromechanical interference, we would expect
that they would not be present at or near the time of death.
We were unable to correlate the wide EGM signals with
surface electrocardiographic tracings or other clinical vari-
ables, which could prove our hypothesis that these signals
represent EMD. However, the clinical setting in which these
Figure 5. Examples of wide EGMs.
Panel 1 depicts a wide rhythm, with
EGM signals .158 ms (A). This is
interpreted as VT by the device, and
antitachycardia pacing is delivered (B),
without an appreciable change in the
arrhythmia. The wide EGM signals
continue and become progressively
more disorganized toward the end of
the episode (C). The device detects a
spontaneous termination of the tachy-
arrhythmia after delivery of antitachy-
cardia pacing. Panel 2 depicts an ex-
tremely wide signal that is interpreted
by the ICD as VF (A), and a shock is
delivered (B). After the shock, the
EGM signal remains extremely wide
(C), although somewhat less fraction-
ated. The postshock EGM is inter-
preted by the device as depicting suc-
cessful termination of VF. Panel 3
depicts an extremely wide signal (A),
as well as noncapturing pacing spikes
from a permanent VVI pacemaker
that had also been implanted (B). The
wide EGM is sensed by the device as
VF, and a shock is delivered (C), which
terminates all spontaneous electrical
activity. After the shock, ineffective
bradycardic pacing continues (D).
Table 3. Characteristics of Wide Intracardiac Electrograms
SCD NSCD p Value
Wide EGMs (n) 17/19 13/18 0.7
Cycle length of wide
EGM (ms)
848 6 247 757 6 251 0.3
Width of wide EGM
(ms)
295 6 150 227 6 69 0.08
Wide EGMS denotes the fraction of patients in each group with stored EGMs
recorded within the final hour of life that depicted wide signals. Data are presented
as the number of patients or the mean value 6 SD. EGM 5 intracardiac
electrogram; NSCD 5 nonsudden cardiac; SCD 5 sudden cardiac death.
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signals occurred, as well as the highly unusual depolarization
pattern they represent, is strongly suggestive of EMD.
Clinical implications. Despite their proven ability to effec-
tively terminate tachyarrhythmias, some episodes of SCD will
continue to occur in patients with ICDs. These deaths will most
likely occur as a result of EMD or bradyarrhythmias, or both.
Future attempts to utilize stored EGMs to document the
timing and mechanisms responsible for sudden death will
require the development of ICD systems that are able to
record other physiologic variables, such as chest impedance,
pH, instantaneous stroke volume, body temperature, intracar-
diac pressure and body motion. These factors, when combined
with stored EGMs, may allow the ICD to provide valuable
information on the pathophysiologic changes that occur at the
time of death.
We acknowledge Ventritex and the Cadence investigators for allowing us access
to the Cadence trial data base. We also thank William G. Stevenson, MD, for his
review and helpful suggestions, and Mrs. Susan Henry for her secretarial
assistance.
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